Viking Therapeutics has unveiled the final results of its phase 2b VOYAGE trial of oral small molecule VK2809 in metabolic ...

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal ...